VSIG4, a surface marker specifically expressed in macrophages and certain tumor cells, showed positive correlations with M1 and M2 macrophages, CD8+ T cells and activated CD4+ memory T cells, γδT ...

Notably, tumor marker pseudoprogression has also been observed in gastric cancer, in addition to lung cancer and HCC, suggesting it could be a broader phenomenon across cancer types (15, 37–39).

Biohybrid microrobots, based on swimming microalgae, offer outstanding self-propulsion and functionalization capabilities, making them promising platforms for cargo loading and delivery. However, ...

Integrated single-cell RNA-seq analysis identifies ferroptosis-driven tumor microenvironment ... LYVE1, SLC40A1, and CD163 were highly expressed in the M_C1 subpopulation. Studies have shown that ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was associated with significantly improved overall survival in a phase 3 trial ...

Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows. Use of Gilead’s Trodelvy, Merck’s Keytruda together could change practice, experts say ...

Lower concentrations of small dense LDL cholesterol (sdLDL-C) and higher levels of ApoB48, a fat-transport marker, are associated with reduced Alzheimer's disease risk. Unexpectedly, ...

A pioneering biobattery has been shown to reduce tumor growth in the body and could hold the key to a new drug-free immunotherapy treatment in cancer patients.

Clinical utility of a tumor-naïve circulating tumor DNA (ctDNA) test to predict outcomes in patients with advanced testicular germ cell tumors. Treatment of poor-risk non seminomatous germ-cell tumors ...

Background: Since 2014, adaptation of chemotherapy based on tumor marker decline after the cycle of BEP (Bleomycin, Etoposide, Cisplatin) is a standard for patients with IGCCCG poor-risk NSGCT based ...